Business
Astrana Health, Inc. Reports Second Quarter 2025 Results
Company to Host Conference Call on Thursday, August 7, 2025, at 2:30 p.m. PT/5:30 p.m. ET Reports total revenue of $654.8 million and adjusted EBITDA of $48.1
About this update from Astrana Health Inc.
[{"type":"text","content":"Company to Host Conference Call on Thursday, August 7, 2025, at 2:30 p.m. PT/5:30 p.m. ET\nReports total revenue of $654.8 million and adjusted EBITDA of $48.1 million, both at the higher end of guidanceContinues to manage medical cost trends effectively, with trend within expectations across all lines of businessReiterates full-year 2025 guidance which is inclusive of the now-closed Prospect Health acquisitionALHAMBRA, Calif., Aug. 7, 2025 /PRNewswire/ -- Astrana Health, Inc. (\"Astrana,\" and together with its subsidiaries and affiliated entities, the \"Company\") (NASDAQ: ASTH), a leading provider-centric, technology-powered healthcare company enabling providers to deliver accessible, high-quality, and high-value care to all, today announced its consolidated financial results for the second quarter ended June 30, 2025.\n\n \n \n \n \n \n \n\n \n\"Astrana Health's strong second quarter results underscore the power of our physician-focused, technology-enabled model to drive profitable growth and deliver better outcomes at scale,\" said Brandon Sim, President and CEO of Astrana Health. \"Our unique ability to build longitudinal relationships with our patients, paired with leading clinical capabilities and a purpose-built technology platform affording us real-time visibility of our patients' health, allows us to operate from a position of strength in a complex and evolving healthcare landscape. As we look ahead, we remain focused on disciplined execution and expanding access to high-quality, coordinated care for the patients and communities we serve.\"\nFinancial Highlights for Second Quarter Ended June 30, 2025:\nAll comparisons are to the three months ended June 30, 2024 unless otherwise stated.\nTotal revenue of $654.8 million, up 35% from $486.3 millionCare Partners revenue of $631.4 million, up 36% from $463.3 millionNet income attributable to Astrana of $9.4 millionEarnings per share - diluted (\"EPS - diluted\") of $0.19Adjusted EBITDA(1) of $48.1 millionFinancial Highlights for Six Months Ended June 30, 2025:\nAll comparisons are to the six months ended June 30, 2024 unless otherwise stated.\nTotal revenue of $1,275.2 million, up 43% from $890.6 millionCare Partners revenue of $1,232.4 million, up 46% from $845.6 millionNet income attributable to Astrana of $16.1 millionEarnings per share - diluted (\"EPS - diluted\") of ...